NeuroSense Therapeutics (NRSN) April 2024 Investor Presentation

NeuroSense Therapeutics is developing novel therapies for neurodegenerative diseases including ALS (amyotrophic lateral sclerosis). The company presented significant top-line results from its Phase 2b clinical trial, with biomarker results expected in H1 2024 and an expedited regulatory pathway under orphan drug designation.